 | • レポートコード：MRC2-11QY10866 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗糖尿病治療薬のグローバル市場について調査・分析したレポートです。種類別（ビグアニド、スルホニル尿素、メグリチニド、チアゾリジンジオン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤）市場規模、用途別（I型糖尿病、II型糖尿病、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗糖尿病治療薬の競争状況、市場シェア ・世界の抗糖尿病治療薬市場：種類別市場規模 2015年-2020年（ビグアニド、スルホニル尿素、メグリチニド、チアゾリジンジオン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤） ・世界の抗糖尿病治療薬市場：種類別市場規模予測 2021年-2026年（ビグアニド、スルホニル尿素、メグリチニド、チアゾリジンジオン、ジペプチジルペプチダーゼIV阻害剤、α-グルコシダーゼ阻害剤） ・世界の抗糖尿病治療薬市場：用途別市場規模 2015年-2020年（I型糖尿病、II型糖尿病、その他） ・世界の抗糖尿病治療薬市場：用途別市場規模予測 2021年-2026年（I型糖尿病、II型糖尿病、その他） ・北米の抗糖尿病治療薬市場分析：米国、カナダ ・ヨーロッパの抗糖尿病治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗糖尿病治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗糖尿病治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗糖尿病治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Astra Zeneca、Boehringer Ingelheim、Eli Lilly、Johnson & Johnson、Merck、Novartis、Novo Nordisk、Sanofi、Teva Pharmaceutical Industries ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.
Market Analysis and Insights: Global Anti-Diabetic Drugs Market
The global Anti-Diabetic Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Anti-Diabetic Drugs Scope and Market Size
Anti-Diabetic Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Diabetic Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Market segment by Type, the product can be split into
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors
Market segment by Application, split into
Type I Diabetes
Type II Diabetes
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Anti-Diabetic Drugs Revenue
1.4 Market by Type
1.4.1 Global Anti-Diabetic Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Biguanides
1.4.3 Sulfonylureas
1.4.4 Meglitinides
1.4.5 Thiazolidinediones
1.4.6 Dipeptidyl Peptidase IV Inhibitors
1.4.7 α-Glucosidase Inhibitors
1.5 Market by Application
1.5.1 Global Anti-Diabetic Drugs Market Share by Application: 2020 VS 2026
1.5.2 Type I Diabetes
1.5.3 Type II Diabetes
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Anti-Diabetic Drugs Market Perspective (2015-2026)
2.2 Global Anti-Diabetic Drugs Growth Trends by Regions
2.2.1 Anti-Diabetic Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Anti-Diabetic Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Anti-Diabetic Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Anti-Diabetic Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Anti-Diabetic Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Anti-Diabetic Drugs Players by Market Size
3.1.1 Global Top Anti-Diabetic Drugs Players by Revenue (2015-2020)
3.1.2 Global Anti-Diabetic Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Anti-Diabetic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Anti-Diabetic Drugs Market Concentration Ratio
3.2.1 Global Anti-Diabetic Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Anti-Diabetic Drugs Revenue in 2019
3.3 Anti-Diabetic Drugs Key Players Head office and Area Served
3.4 Key Players Anti-Diabetic Drugs Product Solution and Service
3.5 Date of Enter into Anti-Diabetic Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-Diabetic Drugs Historic Market Size by Type (2015-2020)
4.2 Global Anti-Diabetic Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Anti-Diabetic Drugs Market Size by Application (2015-2020)
5.2 Global Anti-Diabetic Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Anti-Diabetic Drugs Market Size (2015-2020)
6.2 Anti-Diabetic Drugs Key Players in North America (2019-2020)
6.3 North America Anti-Diabetic Drugs Market Size by Type (2015-2020)
6.4 North America Anti-Diabetic Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Anti-Diabetic Drugs Market Size (2015-2020)
7.2 Anti-Diabetic Drugs Key Players in Europe (2019-2020)
7.3 Europe Anti-Diabetic Drugs Market Size by Type (2015-2020)
7.4 Europe Anti-Diabetic Drugs Market Size by Application (2015-2020)
8 China
8.1 China Anti-Diabetic Drugs Market Size (2015-2020)
8.2 Anti-Diabetic Drugs Key Players in China (2019-2020)
8.3 China Anti-Diabetic Drugs Market Size by Type (2015-2020)
8.4 China Anti-Diabetic Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Anti-Diabetic Drugs Market Size (2015-2020)
9.2 Anti-Diabetic Drugs Key Players in Japan (2019-2020)
9.3 Japan Anti-Diabetic Drugs Market Size by Type (2015-2020)
9.4 Japan Anti-Diabetic Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Anti-Diabetic Drugs Market Size (2015-2020)
10.2 Anti-Diabetic Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Anti-Diabetic Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Anti-Diabetic Drugs Market Size by Application (2015-2020)
11 India
11.1 India Anti-Diabetic Drugs Market Size (2015-2020)
11.2 Anti-Diabetic Drugs Key Players in India (2019-2020)
11.3 India Anti-Diabetic Drugs Market Size by Type (2015-2020)
11.4 India Anti-Diabetic Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Anti-Diabetic Drugs Market Size (2015-2020)
12.2 Anti-Diabetic Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Anti-Diabetic Drugs Market Size by Type (2015-2020)
12.4 Central & South America Anti-Diabetic Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Astra Zeneca
13.1.1 Astra Zeneca Company Details
13.1.2 Astra Zeneca Business Overview
13.1.3 Astra Zeneca Anti-Diabetic Drugs Introduction
13.1.4 Astra Zeneca Revenue in Anti-Diabetic Drugs Business (2015-2020))
13.1.5 Astra Zeneca Recent Development
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Details
13.2.2 Boehringer Ingelheim Business Overview
13.2.3 Boehringer Ingelheim Anti-Diabetic Drugs Introduction
13.2.4 Boehringer Ingelheim Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.2.5 Boehringer Ingelheim Recent Development
13.3 Eli Lilly
13.3.1 Eli Lilly Company Details
13.3.2 Eli Lilly Business Overview
13.3.3 Eli Lilly Anti-Diabetic Drugs Introduction
13.3.4 Eli Lilly Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.3.5 Eli Lilly Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Anti-Diabetic Drugs Introduction
13.4.4 Johnson & Johnson Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Anti-Diabetic Drugs Introduction
13.5.4 Merck Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Anti-Diabetic Drugs Introduction
13.6.4 Novartis Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Novo Nordisk
13.7.1 Novo Nordisk Company Details
13.7.2 Novo Nordisk Business Overview
13.7.3 Novo Nordisk Anti-Diabetic Drugs Introduction
13.7.4 Novo Nordisk Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.7.5 Novo Nordisk Recent Development
13.8 Sanofi
13.8.1 Sanofi Company Details
13.8.2 Sanofi Business Overview
13.8.3 Sanofi Anti-Diabetic Drugs Introduction
13.8.4 Sanofi Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.8.5 Sanofi Recent Development
13.9 Teva Pharmaceutical Industries
13.9.1 Teva Pharmaceutical Industries Company Details
13.9.2 Teva Pharmaceutical Industries Business Overview
13.9.3 Teva Pharmaceutical Industries Anti-Diabetic Drugs Introduction
13.9.4 Teva Pharmaceutical Industries Revenue in Anti-Diabetic Drugs Business (2015-2020)
13.9.5 Teva Pharmaceutical Industries Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Anti-Diabetic Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Anti-Diabetic Drugs Revenue
Table 3. Ranking of Global Top Anti-Diabetic Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Anti-Diabetic Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Biguanides
Table 6. Key Players of Sulfonylureas
Table 7. Key Players of Meglitinides
Table 8. Key Players of Thiazolidinediones
Table 9. Key Players of Dipeptidyl Peptidase IV Inhibitors
Table 10. Key Players of α-Glucosidase Inhibitors
Table 11. Global Anti-Diabetic Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Anti-Diabetic Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Anti-Diabetic Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Anti-Diabetic Drugs Market Share by Regions (2015-2020)
Table 15. Global Anti-Diabetic Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Anti-Diabetic Drugs Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Anti-Diabetic Drugs Market Growth Strategy
Table 21. Main Points Interviewed from Key Anti-Diabetic Drugs Players
Table 22. Global Anti-Diabetic Drugs Revenue by Players (2015-2020) (Million US$)
Table 23. Global Anti-Diabetic Drugs Market Share by Players (2015-2020)
Table 24. Global Top Anti-Diabetic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Diabetic Drugs as of 2019)
Table 25. Global Anti-Diabetic Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Anti-Diabetic Drugs Product Solution and Service
Table 28. Date of Enter into Anti-Diabetic Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 31. Global Anti-Diabetic Drugs Market Size Share by Type (2015-2020)
Table 32. Global Anti-Diabetic Drugs Revenue Market Share by Type (2021-2026)
Table 33. Global Anti-Diabetic Drugs Market Size Share by Application (2015-2020)
Table 34. Global Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 35. Global Anti-Diabetic Drugs Market Size Share by Application (2021-2026)
Table 36. North America Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 38. North America Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 39. North America Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 40. North America Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 41. North America Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 42. Europe Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 44. Europe Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 46. Europe Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 48. China Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 49. China Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 50. China Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 51. China Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 52. China Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 53. China Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 54. Japan Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 56. Japan Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 58. Japan Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 62. Southeast Asia Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 64. Southeast Asia Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 66. India Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 67. India Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 68. India Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 69. India Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 70. India Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 71. India Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Anti-Diabetic Drugs Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Anti-Diabetic Drugs Market Share (2019-2020)
Table 74. Central & South America Anti-Diabetic Drugs Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Anti-Diabetic Drugs Market Share by Type (2015-2020)
Table 76. Central & South America Anti-Diabetic Drugs Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Anti-Diabetic Drugs Market Share by Application (2015-2020)
Table 78. Astra Zeneca Company Details
Table 79. Astra Zeneca Business Overview
Table 80. Astra Zeneca Product
Table 81. Astra Zeneca Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 82. Astra Zeneca Recent Development
Table 83. Boehringer Ingelheim Company Details
Table 84. Boehringer Ingelheim Business Overview
Table 85. Boehringer Ingelheim Product
Table 86. Boehringer Ingelheim Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 87. Boehringer Ingelheim Recent Development
Table 88. Eli Lilly Company Details
Table 89. Eli Lilly Business Overview
Table 90. Eli Lilly Product
Table 91. Eli Lilly Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 92. Eli Lilly Recent Development
Table 93. Johnson & Johnson Company Details
Table 94. Johnson & Johnson Business Overview
Table 95. Johnson & Johnson Product
Table 96. Johnson & Johnson Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 97. Johnson & Johnson Recent Development
Table 98. Merck Company Details
Table 99. Merck Business Overview
Table 100. Merck Product
Table 101. Merck Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 102. Merck Recent Development
Table 103. Novartis Company Details
Table 104. Novartis Business Overview
Table 105. Novartis Product
Table 106. Novartis Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 107. Novartis Recent Development
Table 108. Novo Nordisk Company Details
Table 109. Novo Nordisk Business Overview
Table 110. Novo Nordisk Product
Table 111. Novo Nordisk Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 112. Novo Nordisk Recent Development
Table 113. Sanofi Business Overview
Table 114. Sanofi Product
Table 115. Sanofi Company Details
Table 116. Sanofi Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 117. Sanofi Recent Development
Table 118. Teva Pharmaceutical Industries Company Details
Table 119. Teva Pharmaceutical Industries Business Overview
Table 120. Teva Pharmaceutical Industries Product
Table 121. Teva Pharmaceutical Industries Revenue in Anti-Diabetic Drugs Business (2015-2020) (Million US$)
Table 122. Teva Pharmaceutical Industries Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-Diabetic Drugs Market Share by Type: 2020 VS 2026
Figure 2. Biguanides Features
Figure 3. Sulfonylureas Features
Figure 4. Meglitinides Features
Figure 5. Thiazolidinediones Features
Figure 6. Dipeptidyl Peptidase IV Inhibitors Features
Figure 7. α-Glucosidase Inhibitors Features
Figure 8. Global Anti-Diabetic Drugs Market Share by Application: 2020 VS 2026
Figure 9. Type I Diabetes Case Studies
Figure 10. Type II Diabetes Case Studies
Figure 11. Others Case Studies
Figure 12. Anti-Diabetic Drugs Report Years Considered
Figure 13. Global Anti-Diabetic Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Anti-Diabetic Drugs Market Share by Regions: 2020 VS 2026
Figure 15. Global Anti-Diabetic Drugs Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Anti-Diabetic Drugs Market Share by Players in 2019
Figure 18. Global Top Anti-Diabetic Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Diabetic Drugs as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Anti-Diabetic Drugs Revenue in 2019
Figure 20. North America Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Anti-Diabetic Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
糖尿病網膜症（DR）治療薬の世界市場（～2026年） Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes. The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising…- 黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（～2026年） Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which b…
- 抗レトロウイルス薬の世界市場（～2026年） Market Analysis and Insights: Global Anti-Retroviral Drugs Market The global Anti-Retroviral Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Anti-Retroviral Drugs Scope and Market Size Anti-Retroviral Drugs marke…
- 糖尿病性腎症の世界市場（～2026年） Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 …
- 抗腫瘍薬の世界市場（～2026年） Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be subcategorized as benign and malignant. Benign is not destructive however, possess a potential to turn into a malignant tumor... It ha…